Paragraph IV Certification Explained
What is a Paragraph IV certification?
A Paragraph IV certification is a statement in a US generic drug application (an ANDA) that a patent listed for the brand-name drug "is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the ANDA is submitted." It is the fourth of the patent certifications FDA requires under 21 CFR 314.94(a)(12), and the applicant "must entitle such a certification 'Paragraph IV Certification'" [1]. In practice it challenges the brand's patent and usually sets off patent litigation.
Approach: I read the current eCFR text of 21 CFR Part 314: §314.94 (ANDA content), §314.95 (notice) and §314.107 (approval timing).
Where it fits
For each patent that claims the reference listed drug or a use the applicant is seeking approval for, the ANDA applicant must give the patent number and certify one of four things [1]:
| Certification | What the applicant certifies |
|---|---|
| Paragraph I | The patent information has not been submitted to FDA |
| Paragraph II | The patent has expired |
| Paragraph III | The date the patent will expire |
| Paragraph IV | The patent is invalid, unenforceable, or will not be infringed |
The regulation prescribes the wording: "I, (name of applicant), certify that Patent No. _____ (is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of) (name of proposed drug product) for which this ANDA is submitted." It must come with a statement that the applicant will meet the notice requirements in §314.95 [1]. An applicant that holds a licence from the patent owner must still file a Paragraph IV certification for that patent, together with a statement that it has been granted a licence [1].
Notice to the patent owner and NDA holder (§314.95)
- Who and how: Notice must go to each patent owner and to the NDA holder, by registered or certified mail or a designated delivery service [2].
- Timing: It must be sent on or after the day the applicant receives FDA's paragraph IV acknowledgment letter, and no later than 20 days after that letter's postmark. A notice sent earlier is invalid [2].
- Content: The notice must cite FD&C Act section 505(j)(2)(B)(iv). It must give a detailed factual and legal basis for the challenge, claim by claim. If the applicant wants to keep the option of a later declaratory-judgment action, it must also offer confidential access to the ANDA [2].
- 45-day window: Receipt of the notice starts the 45-day period under section 505(j)(5)(B)(iii) [2].
What follows (§314.107)
- 30-month stay: If the patent owner or exclusive licensee sues for infringement within 45 days of receiving the notice, FDA may approve the ANDA 30 months after the notice was received. The court can extend or shorten that period. This applies to patents listed before the ANDA was submitted [3].
- New chemical entity drugs: If the brand qualifies for 5-year exclusivity and suit is brought in the right window, the earliest approval date is instead 7½ years after the brand NDA was approved [3].
- Early approval on a court win: If a district court finds the patent invalid, unenforceable or not infringed before the 30 months run out, approval can come on the date judgment is entered [3].
- 180-day exclusivity: FDA will not approve a later Paragraph IV filer's ANDA while a first applicant is eligible for 180-day exclusivity, or during that exclusivity period. The period cannot run past the expiry of the patent it is based on [3].
- If the patent is found infringed: After a final, unappealable decision or a court-entered settlement finding infringement, the applicant must amend to a Paragraph III certification. That rule does not apply if the patent is also held invalid [1].
The same type of certification also applies to 505(b)(2) applications, under §314.50(i) [3].
When does the patent lawsuit delay generic approval?
A patent lawsuit delays generic approval only when it meets three conditions. The patent must have been listed with FDA before the ANDA was submitted. The applicant must have filed a Paragraph IV certification against it. And the patent owner, its representative or the exclusive licensee must sue for infringement within 45 days of receiving the Paragraph IV notice. When all three are met, FDA may approve the ANDA 30 months after the later of the dates the notice was received by any patent owner or by the NDA holder. The court can extend or shorten that period if either party fails to cooperate reasonably in expediting the case [3].
Approach: I read the current eCFR text of 21 CFR 314.107 (date of approval of a 505(b)(2) application or ANDA). All the points below come from that section [3].
No delay from litigation
- No suit within 45 days: the ANDA may be approved once the 45-day period has expired, as long as no other block applies. The 45 days start the day after the recipient gets the notice. If the 45th day falls on a weekend or federal holiday, it moves to the next business day.
- Suit filed but FDA not told: if nobody tells FDA in writing about a timely suit before the later of (a) the end of the 45 days or (b) the end of FDA's review, FDA may approve at that later point. The applicant must notify FDA of any suit within 14 days of its filing.
- Waiver: if the patent owner or exclusive licensee files a valid waiver of the right to sue (in the wording FDA prescribes) before the 45 days run out, FDA may approve as soon as its review is complete.
- Patent listed after the ANDA was submitted: the applicant files an amended Paragraph IV certification and gives notice. FDA may then approve as soon as the applicant documents that the notice was received. The 45-day period "does not apply in these circumstances," and there is no 30-month stay.
Longer delay for new chemical entity drugs If the brand drug has 5-year NCE exclusivity under §314.108(b)(2), the clock is different. The suit must be brought in the 1-year period starting 4 years after the brand's approval, and within 45 days of receiving the notice. The ANDA may then be approved once 7½ years have passed since the brand NDA was approved.
Events before the 30 months (or 7½ years) run out
| Event | Earliest approval |
|---|---|
| District court finds the patent invalid, unenforceable or not infringed | Date judgment is entered, or date of a court-entered settlement order or consent decree saying so |
| District court finds infringement and the applicant appeals | Date the appeals court issues its mandate finding invalidity, unenforceability or non-infringement (or a settlement order or consent decree entered by that court) |
| Infringement judgment not appealed, or upheld on appeal | No earlier than the date the district court sets under 35 U.S.C. 271(e)(4)(A) |
| Preliminary injunction granted | Follows the eventual ruling, under the rows above |
| Patent owner or exclusive licensee consents in writing | On or after the date of the consent |
| Court orders the 30-month or 7½-year period terminated | As the order provides |
| Every timely suit dismissed (with or without prejudice) without a finding of infringement | On or after the date of the dismissal order |
The applicant must send FDA copies of these judgments, orders, injunctions and consents within 14 days of their entry or date.
Points that affect the timeline
- Each patent counts separately: FDA works out the first possible approval date for each relevant patent, and the ANDA may be approved on the last of those dates. Exclusivity (§314.108, orphan, pediatric, or section 505E) can push the date back further; when it does, the latest applicable date governs.
- Tentative approval: while the stay runs, FDA can issue only a tentative approval. A tentative approval is not an approval, and the applicant still needs an approval letter to market.
- Later filers: a subsequent Paragraph IV applicant also cannot be approved while a first applicant is eligible for, or is in, its 180-day exclusivity. FDA may approve subsequent applicants immediately if it concludes the first applicant is not actively pursuing approval.
- Approval issued in error, or a court later orders the approval date delayed: FDA will convert the approval to a tentative approval if appropriate.
Can authorized generics compete during exclusivity?
Yes. Under US law, the brand company can sell an authorized generic during the first Paragraph IV filer's 180-day exclusivity period. The exclusivity only stops FDA from approving other ANDAs, and an authorized generic is not an ANDA product. It is sold under the brand's own approved NDA.
Approach: I read the current eCFR text of 21 CFR Part 314 (§314.3 definitions, §314.107 approval timing, §314.81 annual reports). Part 314 does not say directly whether an authorized generic may compete during exclusivity, so for that point I used the FTC's August 2011 report on authorized generics.
Why the 180-day exclusivity doesn't block it
- What the exclusivity blocks: §314.107(c)(1) says the ANDA of a "subsequent applicant" (a later Paragraph IV filer) "will not be approved during the period when any first applicant is eligible for 180-day exclusivity or during the 180-day exclusivity period of a first applicant" [3]. The rule covers only approval of later ANDAs.
- What an authorized generic is: §314.3 defines it as a listed drug "that has been approved under section 505(c)" of the FD&C Act (the NDA route). It is sold to the retail trade with labelling, packaging, product code, labeler code, trade name or trademark that "differs from that of the listed drug" [4]. So it needs no new approval that the exclusivity could hold up.
- What the courts decided: The FTC report (pp. i-ii) says "the courts have ruled that 180-day exclusivity does not preclude a brand-name company from entering with its own generic because it already has approval for its product; therefore, it can sell an AG during that exclusivity period." It cites Teva Pharm. Indus. Ltd. v. Crawford, 410 F.3d 51 (D.C. Cir. 2005).
Reporting to FDA The NDA holder must list in its annual report the date each authorized generic went on the market, the date it stopped being distributed, and the matching brand name. Each dosage form and strength counts as a separate authorized generic and is listed separately. That part of the report goes to FDA marked "Authorized Generic Submission" (§314.81(b)(2)(ii)(b)) [5].
What it means commercially (FTC findings, 2011 report)
- Prices: When an authorized generic competed during exclusivity, retail generic prices were 4-8% lower and wholesale generic prices 7-14% lower than without one.
- First filer's revenue: Its revenue fell 40-52% during exclusivity, and was 53-62% lower over the 30 months afterwards.
- Timing: About two-thirds of the authorized generics studied were launched after exclusivity had ended, or where there was no exclusivity at all.
- "No-AG" settlement deals: A brand's promise not to launch an authorized generic during the first filer's exclusivity has been a common form of payment in pay-for-delay patent settlements. From FY2004 to FY2010, 39 of 157 settlements with first filers (about 25%) included such a promise, with an average delay of 37.9 months.
These figures come from the FTC report itself and its press release.
So a first filer cannot count on being the only generic for those 180 days. It is protected only from other ANDA generics, and only the brand's own decision (or a contract term) keeps an authorized generic off the market.